Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.

Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.

Licensed seasonal influenza vaccines induce antibody (Ab) responses against influenza hemagglutinin (HA) that are limited in their ability to protect against different strains of influenza. Cytotoxic T lymphocytes recognizing the conserved internal nucleoprotein (NP) and matrix protein (M1) are capa...

Description complète

Détails bibliographiques
Auteurs principaux:	Mullarkey, C, Boyd, A, van Laarhoven, A, Lefevre, E, Veronica Carr, B, Baratelli, M, Molesti, E, Temperton, N, Butter, C, Charleston, B, Lambe, T, Gilbert, S
Format:	Journal article
Langue:	English
Publié:	2013

Documents similaires

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses
par: Antrobus, R, et autres
Publié: (2014)

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.
par: Antrobus, R, et autres
Publié: (2014)

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.
par: Lillie, P, et autres
Publié: (2012)

Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine
par: Powell, T, et autres
Publié: (2013)

Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.
par: Timothy J Powell, et autres
Publié: (2013-01-01)

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
par: Berthoud, T, et autres
Publié: (2011)

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.
par: Antrobus, R, et autres
Publié: (2012)

Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1.
par: Lambe, T, et autres
Publié: (2013)

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.
par: Richard D Antrobus, et autres
Publié: (2012-01-01)

Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies
par: Cécile Janssen, et autres
Publié: (2022-11-01)

Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice
par: Martin C. Langenmayer, et autres
Publié: (2023-06-01)

Adenoviral vectors as novel vaccines for influenza.
par: Coughlan, L, et autres
Publié: (2015)

Novel MVA-based vaccine expressing influenza NP and M1 activates cross-reactive T cell responses in human nasopharynx-associated lymphoid tissue (NALT) (conference abstract)
par: Puksuriwong, S, et autres
Publié: (2018)

T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine.
par: Lambe, T, et autres
Publié: (2012)

T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine
par: Lambe, T, et autres
Publié: (2012)

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
par: Ota, M, et autres
Publié: (2011)

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
par: Ota, M, et autres
Publié: (2011)

Novel bivalent viral-vectored vaccines induce potent humoral and cellular immune responses conferring protection against stringent influenza a virus challenge
par: Tully, C, et autres
Publié: (2017)

Development of NP-Based Universal Vaccine for Influenza A Viruses
par: Ekramy E. Sayedahmed, et autres
Publié: (2024-02-01)

A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed InaCTivated inflUenza vaccine in adultS aged 65 years and above (INVICTUS): a study protocol
par: Swayze, H, et autres
Publié: (2019)

Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responsesResearch in context
par: David Pattinson, et autres
Publié: (2024-05-01)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
par: Pedro M. Folegatti, et autres
Publié: (2019-03-01)

Uneventful Coadministration of Seasonal Influenza and COVID-19 BNT162b2 Vaccines Two Weeks Post-Influenza Vaccination in an Egg-Allergic Subject: A Case Report
par: Anwar A. Sayed
Publié: (2023-05-01)

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial
par: Allison R. Thompson, et autres
Publié: (2019-02-01)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured onthe AGE1.CR.pIX Avian Cell Line
par: Folegatti, P, et autres
Publié: (2019)

Clinical advances in viral-vectored influenza vaccines
par: Sebastian, S, et autres
Publié: (2018)

Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines
par: Saranya Sridhar, et autres
Publié: (2015-04-01)

Clinical Advances in Viral-Vectored Influenza Vaccines
par: Sarah Sebastian, et autres
Publié: (2018-05-01)

Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines
par: Wei Dong, et autres
Publié: (2018-10-01)

Safety of routine childhood vaccine coadministration versus separate vaccination
par: Bauwens, J, et autres
Publié: (2022)

Safety of routine childhood vaccine coadministration versus separate vaccination
par: Simon de Lusignan, et autres
Publié: (2022-09-01)

Preclinical study of immunogenicity of adjuvanted quadrivalent subunit influenza vaccine
par: I. V. Krasilnikov, et autres
Publié: (2022-07-01)

Inactivated recombinant influenza vaccine: the promising direction for the next generation of influenza vaccine
par: Hua Shi, et autres
Publié: (2024-12-01)

Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice
par: Arunkumar, G, et autres
Publié: (2019)

Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge
par: McMahon, M, et autres
Publié: (2019)

Influenza and influenza vaccination in children
par: Viorel ALEXANDRESCU, et autres
Publié: (2017-09-01)

Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach
par: Irene González-Domínguez, et autres
Publié: (2024-11-01)

Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics
par: Kaori Sano, et autres
Publié: (2018-08-01)

Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines
par: Teresa Hauguel, et autres
Publié: (2024-10-01)

Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.
par: Boyd, A, et autres
Publié: (2013)